|Articles|August 6, 2014
Risk and Innovation in Biopharma: A CEO’s Perspective
Author(s)Guest Blogger
In this Applied Clinical Trials article, Kadmon CEO Dr. Sam Waksal talks about the importance of imagination for innovation, current business risks in biopharma, and applying understanding to the concept of Big Data.
Advertisement
In this Applied Clinical Trials article, Kadmon CEO Dr. Sam Waksal talks about the importance of imagination for innovation, current business risks in biopharma, and applying understanding to the concept of Big Data.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Medical Supply Chains at Risk Over Escalating Conflicts in Iran: Report
2
Pharmaceutical Executive Daily: Shah Capital's Plan to Vote Against Novavax Board Nominees
3
Q&A: Supply Chain Fallout From Iran War, Tariff Uncertainty
4
Novavax Stock Increases as Shah Capital Plans to Vote Against Board Nominees
5